Hims & Hers, a San Francisco-based health and wellness platform, announced last month that it will offer access to a compounded GLP-1 weight-loss injections at a competitive price.
"Starting today, we are providing access to compounded GLP-1 treatments for eligible customers at prices starting at $199 monthly," the company said in a news release. "We are providing access to compounded GLP-1s, which means customers can access the same active ingredient as Ozempic and Wegovy without navigating the shortages that are currently limiting access to the medication."
GLP-1 drugs, which are used for both diabetes and obesity, are in strong demand as manufacturers scramble to ramp up supply. Ozempic maker Novo Nordisk said earlier that shortages of the drug will persist through the year because of rising demand and manufacturing capacity constraints.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
